Akari Solutions

Akari Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare and orphan autoimmune and inflammatory diseases. The company's lead product candidate, nomacopan, is a recombinant protein that acts as a dual inhibitor of both the complement C5 and leukotriene B4 (LTB4) pathways. This unique dual-action mechanism is being evaluated in late-stage clinical trials for conditions such as bullous pemphigoid and thrombotic microangiopathy. Additionally, Akari is utilizing its proprietary PASylation technology to develop long-acting versions of its molecules, including PAS-nomacopan for the treatment of geographic atrophy. In 2024, the company expanded its strategic focus through a merger with Peak Bio, adding antibody-drug conjugate (ADC) capabilities to its portfolio.